Posted September 26, 2019
SOUTH PLAINFIELD, NJ – September 9, 2019 – Admera Health today announced the launch of Cardio ScoutTM, which assesses a patient’s genetic disposition for malfunctions of the heart’s electrical system or structure that may increase the risk of it stopping unexpectedly. The test was developed in collaboration with Helix, a population genomics company that provides a comprehensive solution for large-scale genetic testing, and Genome Medical, which delivers virtual genetic care through a nationwide network of genetic specialists. The new Cardio ScoutTM product is now available on the Helix marketplace alongside Admera’s proprietary Inherited Cholesterol Test and Inherited Diabetes Tests.
“Cardio ScoutTM continues Admera’s tradition of launching novel genetic tests that add tremendous value in their ability to help screen, diagnose, treat and monitor patients at risk for cardiac issues. Sudden cardiac death remains one of the largest causes of natural death in the US each year, so there’s still a widespread need for better risk stratification that can lead to preventive interventions and greater survival rates among those affected. If a genetic component is uncovered, Cardio ScoutTM can then help family members understand their likelihood for having sudden cardiac arrest and ways to lower that risk.” commented Admera Health’s President and CEO, Guanghui Hu, PhD. “With this launch, Admera has partnered with Helix and Genome Medical to bring together several areas of expertise and offer consumers the highest quality genetic testing.”
The Cardio ScoutTM test can be ordered by visiting the Helix marketplace (www.helix.com) and filling out a health questionnaire for review by a physician at Genome Medical. Once the test is determined as appropriate by the doctor, a specimen collection kit is sent to the consumer’s home. The kit is registered, the sample collected, and then shipped to Helix’s laboratory for sequencing. Helix shares the relevant genetic data with Admera for interpretation and generation of a report that is sent to the consumer and Genome Medical. Genome Medical provides access to certified genetic counselors who can advise consumers about their results, if desired.
“We are excited to continue working with Admera Health and Genome Medical to offer high-quality genetic testing that is accessible to individuals. We believe in expanding access to genetic testing, including empowering people to take direct control of their health,” said Justin Kao, Co-founder and SVP of Helix. “Cardio ScoutTM is an important product in one of the most relevant therapeutic areas for individuals and for our population health partners – cardiovascular health. This provides our partners with more choice in what they can offer to their communities.”
“Through Genome Medical’s world-class specialists in cardiovascular genetic health, consumers gain expert guidance on the insights that Cardio Scout can offer,” said Lisa Alderson, co-founder and CEO at Genome Medical. “We are glad to be working with Admera Health and Helix to ensure patients fully understand their results and harness the value of this information for themselves and their families. Genetic testing becomes truly meaningful when it provides empowered health care decision-making.”
Helix is a population genomics company with a mission to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix partners with health systems to provide a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery.
Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com.
Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC
About Genome Medical
Genome Medical is a national telegenomics technology and services company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and efficient genomic care delivery platform, it provides expert virtual genetic care for individuals and their families to improve health and well-being. Genome Medical also helps healthcare providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care. The company is shepherding in a new era of genomic medicine by creating easy, efficient access to top genetic experts. Genome Medical is headquartered in South San Francisco. To learn more, visit www.genomemedical.com and follow @GenomeMed.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing clinical research services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
For more information on Admera Health, please contact:
Brady Millican, VP Business Development